

DOH/MQA OUTREACH TO FACILITIES SHIPPED NECC PRODUCTS

10/5/2012
Telephone calls to 8 facilities that received the contaminated lot of MPA from NECC and 4 facilities that received 40mg MPA (not contaminated lots).

10/8/2012
Telephone calls to 78 facilities advising of notice on door, voluntary recall, toll-free hotline, and how to dispose of products. Second site visit to 78 facilities to deliver 10/7/2012 press release.

10/16/2012
Telephone calls to 78 facilities advising that FDA requests notification to patients of potential risk of infection for any injectable products administered after 5/21/2012. Also queried about any drugs administered after 5/21/2012, how many patients, follow-up with patients, and whether facility plans to follow FDA and DOH recommendations.

10/18/2012
Telephone calls to 257 facilities to query about any NECC products in possession, whether separated, plans (return or destroy), and email address. Did not reach 127 facilities.

10/22/2012
Follow-up with 12 facilities that were not reached on 10/19/2012. Contact complete with all 257 facilities.

10/30/2012
Follow-up email to 67 facilities with NECC products to remind them to separate drugs from non-NECC products to reduce risk of accidental administration to patients, link to FDA guidance on returns to NECC, and information on licensed reverse distributors they might wish to contact to take their products.



10/6/2012
Telephone calls and site visits to 78 facilities that received any injectable products compounded by NECC advising of voluntary recall of all products compounded by NECC since 1/1/2012. DOH press release of 10/6/2012 posted on doors. All but 6 facilities were closed at the time.

10/11/2012
Telephone calls to 78 facilities to query about any NECC products in possession, whether NECC products have been inventoried and separated, and whether facility intends to destroy or return drugs to NECC.

10/17/2012
Telephone calls to 177 additional facilities identified as receiving any NECC products after 1/1/12, advising that FDA requests notification to patients of potential risk of Infection for any injectable products Administered after 5/21/2012. Also queried about any drugs administered after 5/21/2012, how many patients, follow-up with patients, and whether facility plans to follow FDA and DOH recommendations.

10/19/2012
Heard back from 5 facilities. Telephone calls and site visits to remaining 122 to query about any NECC products in possession, whether separated, plans (return or destroy), and email address. All but 12 reached. Email sent to 273 addresses with SSG statement, FDA statement, sample letter for contacting patients, and request for information on facility website. 7 email addresses undeliverable and 4 facilities either refused or do not have email. 13 facilities agreed to post information on their website and also gave us their website address to post with list of facilities on DOH website.

10/29/2012
Site visit to 112 facilities with DOH pharmacy permit. Physical check for any NECC products on site, whether drugs separated, and plan for drugs (return or destroy). Photos taken of area where drugs had been segregated. 67 facilities had NECC products segregated. 45 facilities had no NECC drugs on site.